Mediators involved in cyclosporin A nephrotoxicity;MEDIATEURS IMPLIQUES DANS LA NEPHROTOXICITE DE LA CICLOSPORINE A

Therapie

Volumn 52, Issue 4, 1997, Pages 329-333

  Simon, N ^a   Barre J ^a   Jolliet, P ^a   Urien, S ^a,b   Tillement, J P ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b INSERM   (France)

Author keywords

Angiotensin HTGF ; Cyclosporin A; Nephrotoxicity

Indexed keywords

CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; DOPAMINE; ENDOTHELIN; NITRIC OXIDE; OSTEOPONTIN; PROSTAGLANDIN DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; CYCLOSPORIN; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT;

ADRENERGIC SYSTEM; CALCIUM HOMEOSTASIS; CONFERENCE PAPER; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; VASOCONSTRICTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY; KIDNEY DISEASE; PHYSIOLOGY; REVIEW; VASCULARIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; VASOCONSTRICTION;

EID: 0030761745     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Myers BD, Newton L, Boshkos C et al. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 1988; 46: 694-703.
2. Kahan B. Cyclosporine. N Engl J Med 1989; 321 : 1725-1738.
3. Mihatsch MJ, Thiel G, Spichtin HP et al. Findings in kidney transplant after treatment with cyclosporine. Transplant Proc 1983; 15: 2821-2835.
4. Platz K-P, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. Transplantation 1994; 58: 170-178.
5. Bennett WM. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 1995; 43: S3-S7.
6. Morozumi K, Sugito K, Oda A et al. A comparative study of morphological characteristics of renal injuries of cacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? Transplant Proc 1996; 28: 1076-1078.
7. Barros EJG, Boim MA, Ajzen H et al. Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. Kidney Int 1987; 32: 19-52.
8. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Transplantation 1987; 44: 135-141.
9. Bennett WM, DeMattos A, Meyer MM et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
10. 2+ overload in primary cultures of rat renal cortical epithelial cells by cytotoxic concentrations of cyclosporine: A digitized fluorescence imaging study. Toxicology 1995; 95: 155-166.
11. Fournier N, Ducet G, Crevat A. Action of cyclosporine on mitochondrial calcium fluxes. J Bioenerg Biomembr 1987; 19: 297-303.
12. Petronilli V, Nicolli A, Costantini P et al. Regulation of the permeability transition pore, a voltage-dependent mitochondrial channel inhibited by cyclosporin A. Biochim Biophy Acta 1994; 1187: 255-259.
13. Zini R, Simon N, Morin C et al. Inhibition of rat cerebral mitochondrial respiration by cyclosporins A, D, and G and restoration with trimetazidine; CR Acad Sci. 1996; 319: 1098-1092.
14. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int 1985; 28: 767-774.
15. Murray BM, Paller MS. Beneficial effect of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol 1986; 25: S37-S39.
16. Scherrer U, Vissing SF, Morgan BJ et al. Cyclosporin induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693-699.
17. Steigerwalt SP, McCurdy R, Smith S, Lockette W. Role of sympathelic nervous system in cyclosporine hypertension following orthotopic cardiac transplant in man. Kidney Int 1987; 31: 309A.
18. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989; 13: 261-272.
19. 2 synthesis induced by cyclosporin A. Am J Physiol 1986; 251: F581-F587.
20. Deray G, Le Houang P, Achour A et al. Enhancement of cyclosporin A nephrotoxicity by Diclofenac. Clin Nephrol 1987; 22: 213-214.
21. Coffman TM, Smith SR, Creech EA et al. The thromboxane synthetase inhibitor CGS 13080 improves renal allograft function in patients taking cyclosporine A. Kidney Int 1990; 37; 604A.
22. Kim HJ, Kwak JY. Effects of Misoprostol on renal function and plasma endothelin-1 levels during early postoperative stage of living donor renal transplant recipients. Transplant Proc 1996; 28: 1207-1209.
23. Pestana M, Vieira-Coelho MA, Pinto-do-O PC et al. Assessment of renal dopaminergic system activity during cyclosporine A administration in the Rat. Br J Pharmacol 1995; 115: 1349-1358.
24. Brooks DP, Drutz DJ, Ruffolo RR. Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam. J Pharmacol Exp Ther 1990; 254: 375-379.
25. Gardner MP, Houghton DC, Andoh TF et al. Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation 1996; 61: 1506-1512.
26. Bobadilla NA, Tapia E, Franco M et al. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 1994; 37; 604A.
27. Gerkins JF. Cyclosporine treatment of normal rats produces a rise in blood pressure and decreased renal vascular responses to nerve stimulation, vasoconstrictors, and endothelial-dependent dilators. J Pharmacol Exp Ther 1989; 250: 1105.
28. Badr KF, Murray JJ, Breyer MD et al. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. J Clin Invest 1989; 83: 336-342.
29. Langman LJ, Yatscoff RW. Comparison of the effects of cyclosporin G (OG37-325), cyclosporin A, and their metabolites on the release of endothelin and prostacyclin from primary renal and aortic endothelial cell lines. Ther Drug Monit 1994; 16: 450-457.
30. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991; 88: 310-314.
31. Kon V, Badr KF. Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int 1991; 40: 1-12.
32. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation 1995; 60: 89-95.
33. Brooks DP, Continu LC. Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670. Eur J Pharmacol 1995; 294: 571-576.
34. Fisch J et al. The renal hemodynamic response to endothelin in chronic cyclosporine-treated dogs. J Urol 1993; 149: 878-883.
35. Kumano K, Masui N, Soh S et al. Plasma endothelin level following kidney transplantation. Transplant Proc 1994; 26: 2114-2116.
36. Textor SC, Burnett JC, Romero C et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995; 47: 1426-1433.
37. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 1990; 49: 445-452.
38. Shehata M, Cope GH, Johnson TS et al. Cyclosporine enhances the expression of TGF-in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48: 1487-1496.
39. Young BA, Burdmann EA, Johnson RJ et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int 1995; 48: 439-448.
40. Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49: 1141-1151.